Deal of the Day — limited-time pharmacy picks!
daclahep 60mg Tablet

daclahep 60mg Tablet

Prescription requiredRx Required

Salt Composition: Daclatasvir

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

28 tablet

About The Product

Hepatitis C

Daclahep 60 mg tablet is used for the treatment of chronic hepatitis C virus (HCV). It is an antiviral medication often used along with other medications. This medication lowers the viral dose of the hepatitis C virus (HCV) in the blood.

Uses

Chronic hepatitis C virus (HCV) infection

Side Effects

The human body reacts differently to Daclahep 60mg Tablet. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

Some of the common side effects of Daclahep 60mg Tablet are mentioned below:

  • Headache
  • Nausea
  • Unusual tiredness
  • Anemia
  • Insomnia
  • Dizziness
  • Shortness of breath
  • Irregular heartbeat
  • Chest pain
  • Fatigue Allergic reaction
  • Upset stomach
  • Trouble sleeping
  • Memory problems
  • Low blood sugar
  • Vomiting
  • Abdominal cramps
  • Swelling of the mouth, face, tongue, or throat

How To Use

  • Take the dose of Daclahep 60mg Tablet as per your healthcare provider’s prescription.
  • Do not stop taking the medicine suddenly, unless your doctor tells you.
  • This medicine is given under the strict supervision of a doctor.
  • Do not self-administer.
  • Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider.
  • Daclahep 60mg Tablet can be taken without food or with food.
  • The doctor will provide emergency medical treatment.
  • You should not break, crush, or chew the medicine; it should be swallowed as a whole.

How It Works

An antiviral medication, Daclahep 60mg Tablet, is used for the treatment of Hepatitis C virus (HCV) infection. It works by lowering the viral load from the blood; as a result, Infected individuals feel relief from the related symptoms of the chronic hepatitis C infection.

Daclahep 60mg Tablet causes a decrease in serum RNA levels of HCV by stopping the function of the nonstructural protein 5A (NS5A) protein in the replication complex. The effect of this medicine can be easily seen within 2 hours after its oral administration.

Safety Advice

Alcohol
It is advised not to consume alcohol with Daclahep 60mg Tablet because the medicine might interact with alcohol, causing harmful effects on the body of the infected individual. Consult your doctor for further information.
Pregnancy
Do not take Daclahep 60mg Tablet without consulting the doctor. In case of pregnancy, taking Daclahep 60mg Tablet might be unsafe. According to some researchers, this medicine may be harmful to the developing baby.
Breast Feeding
Breastfeeding mothers taking Daclahep 60mg Tablet are advised to consult the doctor first before taking this medicine. According to a few researchers, taking Daclahep 60mg Tablet is known to harm the developing baby, as this medicine can pass to the foetus through breast milk.
Driving
It is advisable not to drive or operate heavy machinery, as one of the side effects of the medicine. It is advisable not to drive or operate heavy machinery after taking Daclahep 60mg Tablet, as you may feel dizzy.
Kidney
Please share your medical history with the doctor before starting Daclahep 60mg Tablet. Do not take Daclahep 60mg Tablet without consulting a doctor, as it may worsen the health condition of the individual.
Liver
Share your medical history with the doctor before starting the Daclahep 60mg Tablet. Do not take Daclahep 60mg Tablet without consulting a doctor, as it may worsen the health condition of the

Missed Doses

  • It is advisable not to miss a dose.
  • If you miss a scheduled dose of this medicine, contact your doctor immediately.

FAQs

During pregnancy, it is not safe to take Daclahep 60mg Tablet as it can cause harm to the unborn baby. Also, during breastfeeding, this medicine must not be used.

Please make sure to consult your healthcare provider regarding the same.

Reference

  1. Al-Nahari MM, Abbassi MM, Ebeid FS, Hassany M, El-Sayed MH, Farid SF. (2023). Pharmacokinetics of daclatasvir in Egyptian adolescents with genotype-4 HCV infection. Antivir Ther. 25(2):101-110 - https://pubmed.ncbi.nlm.nih.gov/32367815/
  2. Gandhi Y, Eley T, Fura A, Li W, Bertz RJ, Garimella T. (2024). Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics. Clin Pharmacokinet. 57(8):911-928 - https://pubmed.ncbi.nlm.nih.gov/29353349/
  3. Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S; HALLMARK-DUAL Study Team. (2024). All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 384(9954):1597-605 - https://research.pasteur.fr/en/publication/all-oral-daclatasvir-plus-asunaprevir-for-hepatitis-c-virus-genotype-1b-a-multinational-phase-3-multicohort-study/
  4. Schreiber J, McNally J, Chodavarapu K, Svarovskaia E, Moreno C. (2023). Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir. Hepatology. 64(3):983–5.
  5. Smolders EJ, Colbers A, de Kanter C, Velthoven-Graafland K, Wolberink LT, van Ewijk-Beneken Kolmer N, et al. (2024). Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers. Br J Clin Pharmacol. 83(10):2225–34.
  6. US Food and Drug Administration. (2025). Highlights of prescribing information: Harvoni. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205834s017lbl.pdf.
  7. Wei L, Zhang M, Xu M, Chuang WL, Lu W, Xie W, Jia Z, Gong G, Li Y, Bae SH, Yang YF, Xie Q, Lin S, Chen X, Niu J, Jia J, Garimella T, Torbeyns A, McPhee F, Treitel M, Yin PD, Mo L. (2024). A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. J Gastroenterol Hepatol. 31(11):1860-1867.
  8. World Health Organization. Hepatitis C fact sheet. (2020). https://www.who.int/news-room/fact-sheets/detail/hepatitis-c.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026